30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Sanofi Viscosupplement Growth in Emerging Markets Offsets U.S. Losses -

Sanofi reported 3Q19 Synvisc revenue of €73MM (USD $82MM), +1.4% vs. 3Q18.

 

  • Sanofi’s U.S. viscosupplement sales rebounded somewhat after 2Q19, in which they were down double-digits year over year
  • Continued strength in emerging markets offset U.S. losses, bringing positive growth for Synvisc for the first time in 2019
  • ORTHOWORLD projects Sanofi full year 2019 Synvisc revenue of $356.1MM, +1.3% vs. 2018

 

ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).

  3Q19 3Q18 % Chg % Chg
Orthobiologics $82.0 $80.9 $1.1 1.4%
  9Mo 19 9Mo 18 % Chg % Chg
Orthobiologics $256.2 $260.7 -$4.5 -1.7%

ORTHOWORLD estimates sales by geographic region as follows ($MM).

  3Q19 3Q18 % Chg % Chg
US $56.2 $57.3 -$1.1 -2.0%
Ex-US $25.8 $23.6 $2.2 9.5%
   Europe $5.6 $5.6 $0.0 0.0%
   Emerging Markets $15.7 $14.6 $1.1 7.7%
   Rest of World $4.5 $3.4 $1.1 33.3%
Total $82.0 $80.9 $1.1 1.4%

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.